serine has been researched along with Adverse Drug Event in 1 studies
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.
serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Safety, tumor response, pharmacokinetics, and pharmacodynamic biomarkers were evaluated." | 2.78 | Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors. ( Bahleda, R; Braghetti, A; Cohen, P; Delmonte, A; Farace, F; Hospitel, M; Lassau, N; Lorusso, P; Sessa, C; Soria, JC; Tolcher, A; Veyrat-Follet, C, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sessa, C | 1 |
| Lorusso, P | 1 |
| Tolcher, A | 1 |
| Farace, F | 1 |
| Lassau, N | 1 |
| Delmonte, A | 1 |
| Braghetti, A | 1 |
| Bahleda, R | 1 |
| Cohen, P | 1 |
| Hospitel, M | 1 |
| Veyrat-Follet, C | 1 |
| Soria, JC | 1 |
1 trial available for serine and Adverse Drug Event
| Article | Year |
|---|---|
Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors.
Topics: Adult; Aged; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug | 2013 |